MINNEAPOLIS, Nov. 02, 2026 (GLOBE NEWSWIRE) — Tactile Systems Tech ology, I c. (“Tactile Medical”; the “Compa y”) (Nasdaq: TCMD), a medical tech ology compa y p ovidi g the apies fo people with ch o ic diso de s, today epo ted fi a cial esults fo the thi d qua te e ded Septembe 30, 2026.
- Total eve ue i c eased 7% yea -ove -yea to $91.9 millio ; eve ue f om ou lymphedema p oduct li e i c eased 13% yea -ove -yea to $81.8 millio
- G oss ma gi expa ded to 77% f om 76% i Q3 2025
- Net i come dec eased to $7.2 millio f om $8.2 millio i Q3 2025
- Adjusted EBITDA was $14.3 millio , compa ed to $14.4 millio i Q3 2025
- Received FDA 510(k) clea a ce expa di g the LymphaTech 3D Sca e ’s i dicatio to aid i the assessme t of lymphedema
- Submitted a 510(k) applicatio to the FDA fo Flexitouch® P o, featu i g e ha ceme ts to the Compa y’s adva ced p eumatic comp essio system
- Appoi ted Steve Kiewiet as Chief Ope ati g Office , with espo sibility fo o de ope atio s a d patie t se vices
- Repu chased $6.2 millio of stock u de the Compa y’s sha e epu chase p og am
“Ou esults u de sco e the st e gth a d du ability of ou co e lymphedema busi ess, which delive ed its fifth co secutive qua te of double-digit yea -ove -yea eve ue g owth, while g oss ma gi expa ded fo the 12th co secutive qua te ,” said She i Dodd, Chief Executive Office of Tactile Medical. “As a ma ket leade i both the basic a d adva ced p eumatic comp essio catego ies, we see substa tial oppo tu ity ahead i a ma ket that emai s sig ifica tly u de pe et ated.”
Ms. Dodd co ti ued, “We a e positio ed to captu e that oppo tu ity th ough th ee co ected st ategic p io ities: expa di g access to ca e, c eati g value ac oss the patie t jou ey, a d b oade i g t eatme t optio s. Togethe , we believe these p io ities p ovide a clea path towa d sustai i g above-ma ket lymphedema g owth, d ivi g ope ati g leve age, a d delive i g sha eholde value ove the lo g te m.”
Total eve ue i the thi d qua te of 2026 i c eased $6.1 millio , o 7%, to $91.9 millio , compa ed to $85.8 millio i the thi d qua te of 2025. The i c ease i total eve ue was att ibutable to a i c ease of $9.5 millio , o 13%, i sales a d e tals of the lymphedema p oduct li e, pa tially offset by a dec ease of $3.4 millio , o 25%, i sales of the ai way clea a ce p oduct li e, p ima ily due to the DME i ve to y t a sitio associated with the lau ch of the Compa y’s ext-ge e atio AffloVest® system i the seco d qua te .
G oss p ofit i the thi d qua te of 2026 i c eased $5.5 millio , o 8%, to $70.5 millio , compa ed to $65.0 millio i the thi d qua te of 2025. G oss ma gi was 77% of eve ue, compa ed to 76% of eve ue i the thi d qua te of 2025. G oss ma gi imp oveme t eflected lowe ma ufactu i g costs a d favo able p oduct mix.
Ope ati g expe ses i the thi d qua te of 2026 i c eased $6.9 millio , o 13%, to $60.9 millio , compa ed to $54.0 millio i the thi d qua te of 2025. The i c ease p ima ily eflected co ti ued i vestme ts to suppo t lo g-te m g owth i itiatives.
Ope ati g i come was $9.6 millio i the thi d qua te of 2026, compa ed to $11.0 millio i the thi d qua te of 2025.
I come tax expe se was $3.0 millio i the thi d qua te of 2026, compa ed to $3.2 millio i the thi d qua te of 2025.
Net i come i the thi d qua te of 2026 was $7.2 millio , o $0.31 pe diluted sha e, compa ed to $8.2 millio , o $0.36 pe diluted sha e, i the thi d qua te of 2025.
Weighted-ave age sha es used to compute diluted et i come pe sha e we e 23.0 millio a d 22.5 millio fo the thi d qua te s of 2026 a d 2025, espectively.
Adjusted EBITDA was $14.3 millio i the thi d qua te of 2026, compa ed to $14.4 millio i the thi d qua te of 2025, as g oss ma gi expa sio was offset by co ti ued i vestme ts to suppo t lo g-te m g owth i itiatives.
Total eve ue fo the i e mo ths e ded Septembe 30, 2026, i c eased $26.9 millio , o 12%, to $252.8 millio , compa ed to $225.9 millio fo the i e mo ths e ded Septembe 30, 2025. The i c ease i total eve ue was att ibutable to a i c ease of $28.8 millio , o 15%, i sales a d e tals of the lymphedema p oduct li e, pa tially offset by a dec ease of $1.9 millio , o 5%, i sales of the ai way clea a ce p oduct li e fo the i e mo ths e ded Septembe 30, 2026, compa ed to the i e mo ths e ded Septembe 30, 2025.
Net i come fo the i e mo ths e ded Septembe 30, 2026, was $13.2 millio , o $0.57 pe diluted sha e, compa ed to $8.5 millio , o $0.36 pe diluted sha e, fo the i e mo ths e ded Septembe 30, 2025.
Weighted-ave age sha es used to compute diluted et i come pe sha e we e 23.1 millio a d 23.3 millio fo the i e mo ths e ded Septembe 30, 2026 a d 2025, espectively.
Adjusted EBITDA was $29.5 millio i the i e mo ths e ded Septembe 30, 2026, compa ed to $21.8 millio i the i e mo ths e ded Septembe 30, 2025.
As of Septembe 30, 2026, the Compa y had $75.1 millio i cash a d o outsta di g bo owi gs u de its c edit ag eeme t, compa ed to $83.4 millio i cash a d o outsta di g bo owi gs u de its c edit ag eeme t as of Decembe 31, 2025. The Compa y epu chased $6.2 millio of its stock du i g the thi d qua te u de its sha e epu chase p og am. As of Septembe 30, 2026, $12.5 millio emai ed available u de the Compa y’s $25.0 millio sha e epu chase p og am, which expi es Novembe 3, 2027.
The Compa y co ti ues to expect full yea 2026 total eve ue i the a ge of $360 millio to $366 millio , ep ese ti g g owth of app oximately 9% to 11% yea -ove -yea , compa ed to total eve ue of $329.5 millio i 2025.
The Compa y ow expects full yea 2026 Adjusted EBITDA i the a ge of $50 millio to $52 millio , compa ed to Adjusted EBITDA of $44.8 millio i 2025. The Compa y’s p io 2026 Adjusted EBITDA guida ce expectatio was $49 millio to $51 millio .
Ma ageme t will host a co fe e ce call with a questio -a d-a swe sessio at 5:00 p.m. Easte Time o Novembe 2, 2026, to discuss the esults of the qua te . Those who would like to pa ticipate may dial 877-407-3088 (201-389-0927 fo i te atio al calle s) a d p ovide access code 13762880. A live webcast of the call will also be p ovided o the i vesto elatio s sectio of the Compa y’s website at i vesto s.tactilemedical.com.
Fo those u able to pa ticipate, a eplay of the call will be available fo two weeks at 877-660-6853 (201-612-7415 fo i te atio al calle s); access code 13762880. The webcast will be a chived at i vesto s.tactilemedical.com.
Tactile Medical is a leade i developi g a d ma keti g at-home the apies fo people suffe i g f om u de se ved, ch o ic co ditio s i cludi g lymphedema, lipedema, ch o ic ve ous i sufficie cy a d ch o ic espi ato y co ditio s by helpi g them live bette a d ca e fo themselves at home. Tactile Medical collabo ates with cli icia s to expa d cli ical evide ce, aise awa e ess, i c ease access to ca e, educe ove all healthca e costs a d imp ove the quality of life fo te s of thousa ds of patie ts each yea .
This elease co tai s fo wa d-looki g stateme ts, i cludi g guida ce fo the full yea 2026. Fo wa d-looki g stateme ts a e ge e ally ide tifiable by the use of wo ds like “may,” “will,” “should,” “could,” “expect,” “a ticipate,” “estimate,” “believe,” “i te d,” “co ti ue,” “co fide t,” “outlook,” “guida ce,” “p oject,” “goals,” “look fo wa d,” “poised,” “desig ed,” “pla ,” “ etu ,” “focused,” “p ospects” o “ emai ” o the egative of these wo ds o othe va iatio s o these wo ds o compa able te mi ology. The eade is cautio ed ot to put u due elia ce o these fo wa d-looki g stateme ts, as these stateme ts a e subject to ume ous facto s a d u ce tai ties outside of the Compa y’s co t ol that ca make such stateme ts u t ue, i cludi g, but ot limited to, the Compa y’s ability to obtai eimbu seme t f om thi d-pa ty paye s fo its p oducts; adve se eco omic co ditio s, i cludi g i flatio , isi g i te est ates o a ecessio ; the adequacy of the Compa y’s liquidity to pu sue its busi ess objectives; p ice i c eases fo supplies a d compo e ts; wage a d compo e t p ice i flatio ; loss of a key supplie o othe supply chai dis uptio s; e t y of ew competito s a d/o competitive p oducts; complia ce with a d cha ges i fede al, state a d local gove me t laws a d egulatio s; tech ological obsolesce ce of, o quality issues with, the Compa y’s p oducts; the Compa y’s ability to expa d its busi ess th ough st ategic acquisitio s; the Compa y’s ability to i teg ate acquisitio s a d elated busi esses; the effects of cu e t a d futu e U.S. a d fo eig t ade policy a d ta iff actio s; o the i ability to ca y out esea ch, developme t a d comme cializatio pla s. I additio , othe facto s that could cause actual esults to diffe mate ially a e discussed i the Compa y’s fili gs with the Secu ities a d Excha ge Commissio (the “SEC”). I vesto s a d secu ity holde s a e u ged to ead these docume ts, which a e available f ee of cha ge o the SEC’s website at http://www.sec.gov. The Compa y u de takes o obligatio to publicly update o evise its fo wa d-looki g stateme ts as a esult of ew i fo matio , futu e eve ts o othe wise.
This p ess elease i cludes the o -GAAP fi a cial measu e of Adjusted EBITDA, which diffe s f om fi a cial measu es calculated i acco da ce with U.S. ge e ally accepted accou ti g p i ciples (“GAAP”). Adjusted EBITDA i this elease ep ese ts et i come, plus i te est expe se, et, o less i te est i come, et, less i come tax be efit o plus i come tax expe se, plus dep eciatio a d amo tizatio , plus stock-based compe satio expe se, plus litigatio – elated costs, plus executive t a sitio costs, plus acquisitio a d i teg atio costs, a d plus cha ge i fai value of co ti ge t co side atio . Reco ciliatio of this o -GAAP fi a cial measu e to its most di ectly compa able GAAP measu e is i cluded i this p ess elease.
This o -GAAP fi a cial measu e is p ese ted because the Compa y believes it is a useful i dicato of its ope ati g pe fo ma ce. Ma ageme t uses this measu e p i cipally as a measu e of the Compa y’s ope ati g pe fo ma ce a d fo pla i g pu poses, i cludi g the p epa atio of the Compa y’s a ual ope ati g pla a d fi a cial p ojectio s. The Compa y believes this measu e is useful to i vesto s as suppleme tal i fo matio a d because it is f eque tly used by a alysts, i vesto s a d othe i te ested pa ties to evaluate compa ies i its i dust y. The Compa y also believes this o -GAAP fi a cial measu e is useful to its ma ageme t a d i vesto s as a measu e of compa ative ope ati g pe fo ma ce f om pe iod to pe iod. I additio , Adjusted EBITDA is used as a pe fo ma ce met ic i the Compa y’s compe satio p og am.
The o -GAAP fi a cial measu e p ese ted i this elease should ot be co side ed as a alte ative to, o supe io to, its espective GAAP fi a cial measu e, as a measu e of fi a cial pe fo ma ce o cash flows f om ope atio s as a measu e of liquidity, o a y othe pe fo ma ce measu e de ived i acco da ce with GAAP, a d it should ot be co st ued to imply that the Compa y’s futu e esults will be u affected by u usual o o – ecu i g items. I additio , Adjusted EBITDA is ot i te ded to be a measu e of f ee cash flow fo ma ageme t’s disc etio a y use, as it does ot eflect ce tai cash equi eme ts such as tax payme ts, debt se vice equi eme ts, capital expe ditu es a d ce tai othe cash costs that may ecu i the futu e. Adjusted EBITDA co tai s ce tai othe limitatio s, i cludi g the failu e to eflect the Compa y’s cash expe ditu es, cash equi eme ts fo wo ki g capital eeds a d cash costs to eplace assets bei g dep eciated a d amo tized. I evaluati g o -GAAP fi a cial measu es, you should be awa e that i the futu e the Compa y may i cu expe ses that a e the same as o simila to some of the adjustme ts i this p ess elease. The Compa y’s p ese tatio of o -GAAP fi a cial measu es should ot be co st ued to imply that its futu e esults will be u affected by a y such adjustme ts. Ma ageme t compe sates fo these limitatio s by p ima ily elyi g o the Compa y’s GAAP esults i additio to usi g o -GAAP fi a cial measu es o a suppleme tal basis. The Compa y’s defi itio of these o -GAAP fi a cial measu es is ot ecessa ily compa able to othe simila ly titled captio s of othe compa ies due to diffe e t methods of calculatio .
| (U audited) | (I thousa ds, except sha e a d pe sha e data) | Cash | $ | 75,110 | $ | 83,446 | Accou ts eceivable, et | 48,304 | 43,876 | Net i vestme t i leases | 14,912 | 15,754 | I ve to ies | 15,596 | 14,025 | I come taxes eceivable | 543 | — | P epaid expe ses a d othe cu e t assets | 12,314 | 8,066 | Total cu e t assets | 166,779 | 165,167 | P ope ty a d equipme t, et | 5,685 | 5,117 | Right of use ope ati g lease assets | 15,282 | 13,798 | I ta gible assets, et | 43,721 | 39,167 | Goodwill | 39,554 | 31,063 | Defe ed i come taxes | 8,695 | 9,783 | Othe o -cu e t assets | 11,578 | 9,847 | Total o -cu e t assets | 124,515 | 108,775 | $ | 291,294 | $ | 273,942 | Accou ts payable | $ | 11,792 | $ | 4,968 | Acc ued pay oll a d elated taxes | 17,470 | 19,378 | Acc ued expe ses | 7,881 | 8,531 | I come taxes payable | — | 1,428 | Ope ati g lease liabilities | 3,245 | 3,195 | Othe cu e t liabilities | 7,111 | 3,457 | Total cu e t liabilities | 47,499 | 40,957 | Acc ued wa a ty ese ve, o -cu e t | 1,092 | 1,045 | I come taxes payable, o -cu e t | 370 | 275 | Ope ati g lease liabilities, o -cu e t | 13,821 | 12,763 | Othe o -cu e t liabilities | 1,260 | — | Total o -cu e t liabilities | 16,543 | 14,083 | 64,042 | 55,040 | P efe ed stock, $0.001 pa value, 50,000,000 sha es autho ized; o e issued a d outsta di g as of Septembe 30, 2026 a d Decembe 31, 2025 | — | — | Commo stock, $0.001 pa value, 300,000,000 sha es autho ized; 22,495,939 sha es issued a d outsta di g as of Septembe 30, 2026; 22,438,926 sha es issued a d outsta di g as of Decembe 31, 2025 | 22 | 22 | Additio al paid-i capital | 159,108 | 163,940 | Retai ed ea i gs | 68,122 | 54,940 | 227,252 | 218,902 | $ | 291,294 | $ | 273,942 |
| (U audited) | (I thousa ds, except sha e a d pe sha e data) | Sales eve ue | $ | 82,329 | $ | 76,890 | $ | 225,784 | $ | 199,890 | Re tal eve ue | 9,529 | 8,865 | 27,039 | 26,038 | Total eve ue | 91,858 | 85,755 | 252,823 | 225,928 | Cost of sales eve ue | 18,400 | 17,896 | 51,287 | 49,270 | Cost of e tal eve ue | 2,969 | 2,858 | 8,084 | 7,518 | Total cost of eve ue | 21,369 | 20,754 | 59,371 | 56,788 | G oss p ofit – sales eve ue | 63,929 | 58,994 | 174,497 | 150,620 | G oss p ofit – e tal eve ue | 6,560 | 6,007 | 18,955 | 18,520 | G oss p ofit | 70,489 | 65,001 | 193,452 | 169,140 | Sales a d ma keti g | 33,042 | 29,809 | 97,786 | 87,364 | Resea ch a d developme t | 2,506 | 2,191 | 7,783 | 5,950 | Reimbu seme t, ge e al a d admi ist ative | 24,657 | 21,442 | 71,061 | 63,474 | I ta gible asset amo tizatio a d co ti ge t co side atio | 693 | 596 | 1,939 | 1,848 | Total ope ati g expe ses | 60,898 | 54,038 | 178,569 | 158,636 | 9,591 | 10,963 | 14,883 | 10,504 | I te est i come | 560 | 667 | 1,787 | 2,412 | I te est expe se | (20 | ) | (193 | ) | (67 | ) | (1,027 | ) | Othe i come | — | — | — | 1 | 10,131 | 11,437 | 16,603 | 11,890 | I come tax expe se | 2,971 | 3,228 | 3,421 | 3,438 | $ | 7,160 | $ | 8,209 | $ | 13,182 | $ | 8,452 | Net i come pe commo sha e | Basic | $ | 0.32 | $ | 0.37 | $ | 0.58 | $ | 0.37 | Diluted | $ | 0.31 | $ | 0.36 | $ | 0.57 | $ | 0.36 | Weighted-ave age commo sha es used to compute et i come pe commo sha e | Basic | 22,632,801 | 22,318,570 | 22,624,676 | 23,035,461 | Diluted | 23,045,862 | 22,513,140 | 23,136,378 | 23,304,900 |
| (U audited) | (I thousa ds) | Net i come | $ | 13,182 | $ | 8,452 | Adjustme ts to eco cile et i come to et cash p ovided by ope ati g activities: | Dep eciatio a d amo tizatio | 5,223 | 5,023 | Defe ed i come taxes | 50 | 1,566 | Stock-based compe satio expe se | 6,416 | 5,819 | Loss o disposal of p ope ty a d equipme t a d i ta gibles | 73 | 68 | Cha ge i fai value of co ti ge t co side atio | 61 | — | Cha ges i assets a d liabilities, et of acquisitio : | Accou ts eceivable, et | (4,409 | ) | 7,680 | Net i vestme t i leases | 842 | (303 | ) | I ve to ies | (1,571 | ) | 2,582 | I come taxes payable | (1,876 | ) | 1,025 | P epaid expe ses a d othe assets | (6,481 | ) | (5,971 | ) | Right of use ope ati g lease assets | (376 | ) | (322 | ) | Accou ts payable | 6,773 | 2,117 | Acc ued pay oll a d elated taxes | (1,908 | ) | (3,196 | ) | Acc ued expe ses a d othe liabilities | (1,106 | ) | 975 | Net cash p ovided by ope ati g activities | 14,893 | 25,515 | Payme ts elated to acquisitio , et of cash acqui ed | (6,226 | ) | — | Pu chases of p ope ty a d equipme t | (2,655 | ) | (1,870 | ) | I ta gible assets expe ditu es | (100 | ) | (88 | ) | Payme t fo exclusive dist ibutio ag eeme t | (3,000 | ) | — | Net cash used i i vesti g activities | (11,981 | ) | (1,958 | ) | Payme ts o ote payable | — | (26,250 | ) | P oceeds f om exe cise of commo stock optio s | 248 | 10 | P oceeds f om the issua ce of commo stock f om the employee stock pu chase pla | 1,032 | 843 | Payme ts fo epu chases of commo stock | (12,528 | ) | (26,562 | ) | Net cash used i fi a ci g activities | (11,248 | ) | (51,959 | ) | (8,336 | ) | (28,402 | ) | Cash – begi i g of pe iod | 83,446 | 94,367 | Cash – e d of pe iod | $ | 75,110 | $ | 65,965 | Cash paid fo i te est | $ | 59 | $ | 836 | Cash paid fo taxes | $ | 5,238 | $ | 899 | Acc ued excise tax o stock epu chases | $ | — | $ | 210 | Capital expe ditu es i cu ed but ot yet paid | $ | 129 | $ | 224 | Fai value of co ti ge t co side atio i cluded i pu chase co side atio | $ | 4,863 | $ | — |
The followi g table summa izes eve ue by p oduct li e fo the th ee a d i e mo ths e ded Septembe 30, 2026 a d 2025:
| (I thousa ds) | Lymphedema p oducts | $ | 81,838 | $ | 72,381 | $ | 217,689 | $ | 188,905 | Ai way clea a ce p oducts | 10,020 | 13,374 | 35,134 | 37,023 | Total | $ | 91,858 | $ | 85,755 | $ | 252,823 | $ | 225,928 | Lymphedema p oducts | 89 | % | 84 | % | 86 | % | 84 | % | Ai way clea a ce p oducts | 11 | % | 16 | % | 14 | % | 16 | % | Total | 100 | % | 100 | % | 100 | % | 100 | % |
The followi g table co tai s a eco ciliatio of et i come to Adjusted EBITDA fo the th ee a d i e mo ths e ded Septembe 30, 2026 a d 2025, as well as the dolla a d pe ce tage cha ge betwee the compa able pe iods:
| (U audited) | (Dolla s i thousa ds) | $ | 7,160 | $ | 8,209 | $ | (1,049 | ) | (13 | )% | $ | 13,182 | $ | 8,452 | $ | 4,730 | 56 | % | I te est (i come) expe se, et | (540 | ) | (474 | ) | (66 | ) | 14 | % | (1,720 | ) | (1,385 | ) | (335 | ) | 24 | % | I come tax (be efit) expe se | 2,971 | 3,228 | (257 | ) | (8 | )% | 3,421 | 3,438 | (17 | ) | (0 | )% | Dep eciatio a d amo tizatio | 1,773 | 1,638 | 135 | 8 | % | 5,223 | 5,023 | 200 | 4 | % | Stock-based compe satio | 2,376 | 1,814 | 562 | 31 | % | 6,416 | 5,819 | 597 | 10 | % | Cha ge i fai value of co ti ge t co side atio | 61 | — | 61 | — | % | 61 | — | 61 | — | % | Acquisitio & i teg atio costs | 159 | — | 159 | — | % | 1,132 | — | 1,132 | — | % | Litigatio – elated costs | — | — | — | — | % | 1,000 | — | 1,000 | — | % | Executive t a sitio costs | 388 | — | 388 | — | % | 748 | 491 | 257 | 52 | % | $ | 14,348 | $ | 14,415 | $ | (67 | ) | (0 | )% | $ | 29,463 | $ | 21,838 | $ | 7,625 | 35 | % |
The followi g table co tai s a eco ciliatio of et i come to Adjusted EBITDA fo the yea e ded Decembe 31, 2025:
| (U audited) | (Dolla s i thousa ds) | $ | 19,086 | I te est (i come) expe se, et | (2,059 | ) | I come tax expe se | 12,253 | Dep eciatio a d amo tizatio | 6,644 | Stock-based compe satio | 8,357 | Executive t a sitio costs | 491 | $ | 44,772 |
The followi g table co tai s a eco ciliatio of the GAAP et i come guida ce a ge to the Adjusted EBITDA guida ce a ge fo the twelve mo ths e di g Decembe 31, 2026:
| (U audited) | (Dolla s i thousa ds) | $ | 23,580 | $ | 25,000 | I te est (i come) expe se, et | (2,370 | ) | (2,370 | ) | I come tax expe se | 9,170 | 9,750 | Dep eciatio a d amo tizatio | 7,250 | 7,250 | Stock-based compe satio | 8,640 | 8,640 | Acquisitio & i teg atio costs | 1,300 | 1,300 | Cha ge i fai value of co ti ge t co side atio | 100 | 100 | Executive t a sitio costs | 1,330 | 1,330 | Litigatio – elated costs | 1,000 | 1,000 | $ | 50,000 | $ | 52,000 |
